Roche extends tender to Ventana once again
TUCSON, Ariz. Roche Holding AG will again extend its tender offer for Ventana Medical Systems, according to the Associated Press.
The bid, which is valued at $3 billion is now set to expire Nov. 1, instead of today. Ventana shareholders have not been in favor of the offer since it was announced back in June. The reason why the two sides cannot agree is because of the valuation of the company. Roche has offered to buy all of Ventana’s outstanding shares for $75 per share. The stock of the company, however, was up to $83.68 as of Wednesday.
Yesterday, Roche said about 63,451 shares have been tendered pursuant to the offer. That is only a small number compared to the 34 million shares Ventana says that it has outstanding.
CVS to offer flu vaccinations in more than 4,000 stores
WOONSOCKET, R.I. CVS/pharmacy plans to help Americans stay healthy by offering flu vaccinations in over 4,000 of its stores, the company said Wednesday.
The flu vaccinations, which will be offered to customers by Oct. 1, will vary in cost based on location. Vaccines for Medicare Part B beneficiaries who present their Medicare Card will be available at no charge, provided they have not assigned their Medicare benefits to a private Health Maintenance Organization. The offer to receive the flu shots will run through November.
“The annual flu shot clinics at CVS/pharmacy are part of our commitment to help communities stay healthy,” said Papatya Tankut, R.Ph., Vice President of Pharmacy Professional Services at CVS/pharmacy. “By offering convenient locations for flu vaccinations, we’re providing additional opportunities for people across the country to get vaccinated before the peak flu season begins.”
Last year, nearly 400,000 people received flu shots at CVS/pharmacy.
It is strongly recommended people ages 50 and older, and/or have chronic illnesses like diabetes and asthma, receive a yearly flu vaccination, according to the Centers for Disease Control.
Adams, Lipocine to develop new cough medicines
CHESTER, N.J. Lipocine and Adams Respiratory Therapeutics have entered in an agreement to develop new prescription adult cough products.
Under the terms of the agreement, Adams receives exclusive rights from Lipocine to develop and market multiple prescription adult cough products. Adams will be responsible for performing clinical development, regulatory submission, manufacture, and commercial operations. Lipocine will be responsible for completing the product development work.
Lipocine will have the opportunity to receive reimbursements and payments in exchange for completing development milestones. “Given the large and growing size of the respiratory market, and how patients can benefit from enhanced dosage forms and regimens, we are very pleased to partner with Adams, a company highly respected for its commercialization accomplishments,” said Dr. Mahesh Patel, president and chief executive officer of Lipocine.